Windsor Private Capital Lp Sells 45,036 Shares of Firefly Neuroscience (NASDAQ:AIFF) Stock

Firefly Neuroscience, Inc. (NASDAQ:AIFF) major shareholder Windsor Private Capital Lp sold 45,036 shares of the firm’s stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $2.55, for a total transaction of $114,841.80. Following the completion of the sale, the insider owned 1,367,526 shares of the company’s stock, valued at $3,487,191.30. This trade represents a 3.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Windsor Private Capital Lp also recently made the following trade(s):

• On Thursday, October 16th, Windsor Private Capital Lp sold 40,139 shares of Firefly Neuroscience stock. The stock was sold at an average price of $2.65, for a total transaction of $106,368.35.
• On Wednesday, October 15th, Windsor Private Capital Lp sold 17,500 shares of Firefly Neuroscience stock. The shares were sold at an average price of $2.74, for a total value of $47,950.00.
• On Tuesday, October 14th, Windsor Private Capital Lp sold 29,500 shares of Firefly Neuroscience stock. The shares were sold at an average price of $2.74, for a total value of $80,830.00.
• On Monday, October 13th, Windsor Private Capital Lp sold 32,136 shares of Firefly Neuroscience stock. The stock was sold at an average price of $2.65, for a total transaction of $85,160.40.
• On Friday, October 10th, Windsor Private Capital Lp sold 74,810 shares of Firefly Neuroscience stock. The stock was sold at an average price of $2.70, for a total value of $201,987.00.
• On Thursday, October 9th, Windsor Private Capital Lp sold 30,126 shares of Firefly Neuroscience stock. The shares were sold at an average price of $2.94, for a total value of $88,570.44.

Firefly Neuroscience Stock Performance

Shares of NASDAQ:AIFF opened at $2.51 on Friday. Firefly Neuroscience, Inc. has a 1 year low of $1.86 and a 1 year high of $17.20. The stock has a 50-day simple moving average of $2.78 and a 200-day simple moving average of $2.97. The stock has a market capitalization of $33.76 million, a P/E ratio of -1.00 and a beta of 2.11.

Firefly Neuroscience (NASDAQ:AIFF) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.14) EPS for the quarter. Firefly Neuroscience had a negative return on equity of 464.02% and a negative net margin of 5,335.75%.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Firefly Neuroscience in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Firefly Neuroscience stock. Geode Capital Management LLC raised its position in Firefly Neuroscience, Inc. (NASDAQ:AIFF) by 92.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 120,604 shares of the company’s stock after purchasing an additional 58,067 shares during the quarter. Geode Capital Management LLC owned about 0.94% of Firefly Neuroscience worth $341,000 as of its most recent filing with the Securities and Exchange Commission. 4.96% of the stock is owned by institutional investors.

About Firefly Neuroscience

Firefly Neuroscience, Inc, a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder.